This suggestion was strongly confirmed by the finding that R-AML was a stronger inhibitor of both CYP2C9 and CYP2C19, having IC50 values against these enzymes that were two- and twelve-fold lower than those for S-AML, respectively (see Table 1). Here, CYP2C19 is linked to acute myeloid leukemia.